Inozyme Pharma (NASDAQ:INZY) Stock Rating Reaffirmed by HC Wainwright

Inozyme Pharma (NASDAQ:INZY)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $14.00 price objective on the stock. HC Wainwright’s target price would suggest a potential upside of 211.80% from the stock’s current price.

Several other research analysts have also issued reports on INZY. Wells Fargo & Company assumed coverage on Inozyme Pharma in a research report on Thursday, May 30th. They issued an “overweight” rating and a $14.00 price target on the stock. Bank of America reduced their price target on Inozyme Pharma from $16.00 to $14.00 and set a “buy” rating on the stock in a research report on Tuesday, April 9th. Needham & Company LLC reiterated a “buy” rating and set a $23.00 target price on shares of Inozyme Pharma in a report on Wednesday, May 8th. Finally, Wedbush reiterated an “outperform” rating and set a $15.00 target price on shares of Inozyme Pharma in a report on Tuesday, May 7th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $16.00.

Inozyme Pharma Stock Up 1.6 %

NASDAQ INZY opened at $4.49 on Tuesday. The stock has a fifty day moving average of $4.60 and a 200-day moving average of $5.09. The stock has a market capitalization of $277.75 million, a P/E ratio of -3.28 and a beta of 1.53. Inozyme Pharma has a 52 week low of $2.69 and a 52 week high of $7.80. The company has a debt-to-equity ratio of 0.38, a quick ratio of 14.05 and a current ratio of 14.05.

Inozyme Pharma (NASDAQ:INZY) last released its earnings results on Tuesday, May 7th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.03). On average, equities research analysts forecast that Inozyme Pharma will post -1.59 EPS for the current year.

Institutional Trading of Inozyme Pharma

Institutional investors have recently modified their holdings of the company. Values First Advisors Inc. acquired a new stake in shares of Inozyme Pharma in the fourth quarter valued at about $59,000. SG Americas Securities LLC increased its position in Inozyme Pharma by 46.9% during the fourth quarter. SG Americas Securities LLC now owns 21,236 shares of the company’s stock worth $90,000 after buying an additional 6,784 shares during the last quarter. Superstring Capital Management LP acquired a new position in Inozyme Pharma during the fourth quarter worth approximately $528,000. Schonfeld Strategic Advisors LLC increased its position in Inozyme Pharma by 346.8% during the third quarter. Schonfeld Strategic Advisors LLC now owns 311,880 shares of the company’s stock worth $1,310,000 after buying an additional 242,080 shares during the last quarter. Finally, Laurion Capital Management LP increased its position in Inozyme Pharma by 170.5% during the third quarter. Laurion Capital Management LP now owns 677,329 shares of the company’s stock worth $2,845,000 after buying an additional 426,961 shares during the last quarter. 88.30% of the stock is currently owned by institutional investors.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.